This is the first study showing that circadian variation in bone resorptive activity significantly differs according to the dosing time of the teriparatide treatment. Our data supports the hypothesis that the response of bone cells to teriparatide treatment differs by its dosing time.
Whether the timing of teriparatide administration will have an impact on the efficacy and safety of long-term teriparatide treatment will need to be further analyzed in prospective studies.